BioMarin (BMRN +2%) gains on an upgrade to Buy at Brean Murray based on increased confidence in...


BioMarin (BMRN +2%) gains on an upgrade to Buy at Brean Murray based on increased confidence in the timing and outcome of its GALNS program to treat MPS IV. The firm believes the treatment could eventually exceed $500M in sales.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs